Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Deferred Taxes: 2012-2024

Historic Deferred Taxes for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $17.9 million.

  • Amphastar Pharmaceuticals' Deferred Taxes fell 26.79% to $2.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was $2.9 million, marking a year-over-year decrease of 46.39%. This contributed to the annual value of $17.9 million for FY2024, which is 42.09% up from last year.
  • Amphastar Pharmaceuticals' Deferred Taxes amounted to $17.9 million in FY2024, which was up 42.09% from $12.6 million recorded in FY2023.
  • Amphastar Pharmaceuticals' 5-year Deferred Taxes high stood at $17.9 million for FY2024, and its period low was -$2.4 million during FY2021.
  • In the last 3 years, Amphastar Pharmaceuticals' Deferred Taxes had a median value of $16.4 million in 2022 and averaged $15.6 million.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Deferred Taxes tumbled by 1,574.07% in 2021, and later spiked by 788.65% in 2022.
  • Amphastar Pharmaceuticals' Deferred Taxes (Yearly) stood at $162,000 in 2020, then crashed by 1,574.07% to -$2.4 million in 2021, then soared by 788.65% to $16.4 million in 2022, then fell by 23.51% to $12.6 million in 2023, then skyrocketed by 42.09% to $17.9 million in 2024.